Cogent Biosciences: Funding, Investors & Team (Oct 2026)
Pertinent Biosciences utilizes restrictive T-cell designing innovation in blend with growth focusing on antibodies to actuate the body's own resistant framework to battle disease. Unum's lead program, in view of its Antibody-Coupled T-cell Receptor (ACTR) innovation, is supposed to enter Phase I clinical testing before long to evaluate wellbeing and viability. Unum is looking for accomplices keen on utilizing the ACTR innovation to arm restrictive growth explicit antibodies with a T-cell to work on their restorative potential. The organization is settled in Cambridge, Massachusetts.
Cogent Biosciences has raised $350M across 3 funding rounds on record, the most recent an undisclosed round of $50.0M announced in Jun 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cogent Biosciences Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Cogent Biosciences Funding Rounds
Cogent Biosciences raised $150M in a Post-IPO Equity announced in Jun 2022.
1 years later, an undisclosed round of $150M was announced in Jun 2023.
2 years later, an undisclosed round of $50.0M was announced in Jun 2025.
Cogent Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Cogent Biosciences Funding Compared to Other Biotechnology Startups
Cogent Biosciences' latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cogent Biosciences in Biotechnology and Cambridge
Companies Similar to Cogent Biosciences
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Cogent Biosciences Funding FAQs
What does Cogent Biosciences do?
Pertinent Biosciences utilizes restrictive T-cell designing innovation in blend with growth focusing on antibodies to actuate the body's own resistant framework to battle disease. Unum's lead program, in view of its Antibody-Coupled T-cell Receptor (ACTR) innovation, is supposed to enter Phase I clinical testing before long to evaluate wellbeing and viability. Unum is looking for accomplices keen on utilizing the ACTR innovation to arm restrictive growth explicit antibodies with a T-cell to work on their restorative potential. The organization is settled in Cambridge, Massachusetts.
How much funding has Cogent Biosciences raised?
Cogent Biosciences has raised $350M across 3 rounds on record. The most recent is an undisclosed round of $50.0M announced in Jun 2025.
When did Cogent Biosciences last raise funding?
Cogent Biosciences' most recent funding round on record is an undisclosed round of $50.0M, announced in Jun 2025.
Who founded Cogent Biosciences?
FundedIQ lists Dario Campana (Founder) at Cogent Biosciences.
Where is Cogent Biosciences headquartered?
Cogent Biosciences is based in Cambridge, Massachusetts, United States.
How many employees does Cogent Biosciences have?
Cogent Biosciences is in the 101-250 employee band.
How does Cogent Biosciences' funding compare to other Biotechnology startups?
Cogent Biosciences' latest round of $50.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Cogent Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cogent Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.